Shares of NewLink Genetics Corp. (NASDAQ:NLNK) were down 5.4% on Wednesday . The company traded as low as $10.93 and last traded at $11.00, with a volume of 204,399 shares. The stock had previously closed at $11.63.

A number of analysts have recently weighed in on NLNK shares. Stifel Nicolaus reduced their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Robert W. Baird started coverage on shares of NewLink Genetics Corp. in a report on Tuesday, March 22nd. They issued an “outperform” rating and a $27.00 target price on the stock. Mizuho reduced their target price on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald restated a “buy” rating and issued a $62.00 target price on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Finally, SunTrust Banks Inc. downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $59.00 to $12.00 in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. NewLink Genetics Corp. presently has an average rating of “Hold” and a consensus target price of $23.29.

The stock’s market cap is $315.45 million. The company’s 50-day moving average is $11.18 and its 200 day moving average is $18.15.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings results on Friday, April 29th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.70) by $0.88. The firm had revenue of $4.34 million for the quarter, compared to analyst estimates of $2.08 million. Analysts predict that NewLink Genetics Corp. will post ($2.83) earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in NLNK. EQIS Capital Management raised its stake in NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares in the last quarter. Russell Frank Co raised its stake in NewLink Genetics Corp. by 57.1% in the fourth quarter. Russell Frank Co now owns 265,422 shares of the company’s stock valued at $9,712,000 after buying an additional 96,512 shares in the last quarter. California State Teachers Retirement System raised its stake in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares in the last quarter. GSA Capital Partners LLP raised its stake in NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares in the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.